Recent Updates
Recently added Catalysts
EW Positive Sentiment Score: 68/100

Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Meshulam, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826

Key Takeaway: Edwards Lifesciences has announced a planned transition of its Chief Financial Officer, Scott Ullem, who will depart by mid-2026. The company is starting the selection process for a new CFO and aims to ensure a smooth transfer of responsibilities during this transition. Following the appointment of a successor, Ullem will remain with the company in an advisory position.

Market Sentiment Analysis

POSITIVE FACTORS

  • Planned CFO transition indicates proactive management.
  • Scott Ullem will continue in an advisory role post-transition.
  • The transition aims to ensure continuity and smooth responsibility transfer.

Full Press Release Details

FOR IMMEDIATE RELEASE
Media Contact: Amy Meshulam, 949-250-4009
Investor Contact: Mark Wilterding, 949-250-6826
EDWARDS LIFESCIENCES ANNOUNCES CFO TRANSITION PLAN
IRVINE, Calif. , Oct. 30, 2025 - Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.
About Edwards Lifesciences
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as "may," "might," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "intend," "optimistic," "aspire," "confident" and other forms of these words and include, but are not limited to, statements regarding the plan to transition Mr. Ullem, including the timing of the transition, and the transition goals of enabling continuity and a smoother transfer, as well as Mr. Ullem continuing in an advisory role and other statements that are not historical facts . Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, and the stylized E logo, are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

Frequently Asked Questions

Who is transitioning from CFO at Edwards Lifesciences?

Scott Ullem, the current CFO, is transitioning from his role.

When will Scott Ullem transition from his CFO role?

He plans to transition by midyear 2026.

What will happen after a new CFO is appointed?

Ullem will continue to serve in an advisory role.

What is the purpose of this CFO transition?

The transition aims to ensure continuity and smooth responsibility transfer.

Where can I find more information about Edwards Lifesciences?

Visit Edwards.com for detailed filings and safety information.

Last updated: Oct 30, 2025